Yue-Zhong Wu

3.3k total citations · 1 hit paper
16 papers, 1.1k citations indexed

About

Yue-Zhong Wu is a scholar working on Hematology, Cancer Research and Molecular Biology. According to data from OpenAlex, Yue-Zhong Wu has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 8 papers in Cancer Research and 7 papers in Molecular Biology. Recurrent topics in Yue-Zhong Wu's work include Acute Myeloid Leukemia Research (11 papers), Cancer Genomics and Diagnostics (4 papers) and MicroRNA in disease regulation (3 papers). Yue-Zhong Wu is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Cancer Genomics and Diagnostics (4 papers) and MicroRNA in disease regulation (3 papers). Yue-Zhong Wu collaborates with scholars based in United States and Germany. Yue-Zhong Wu's co-authors include Sebastian Schwind, Michael A. Caligiuri, Susan P. Whitman, Heiko Becker, Guido Marcucci, Krzysztof Mrózek, Clara D. Bloomfield, Andrew J. Carroll, Jonathan E. Kolitz and Kati Maharry and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Yue-Zhong Wu

16 papers receiving 1.1k citations

Hit Papers

IDH1 and IDH2 Gene Mutations Identify Novel Molecular Sub... 2010 2026 2015 2020 2010 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
    2010 548 citations Guido Marcucci, Kati Maharry et al. Journal of Clinical Oncology profile →

Peers

Yue-Zhong Wu
Comparison fields: 5 of 48
  • Hematology 770
  • Molecular Biology 670
  • Cancer Research 396
  • Genetics 311
  • Public Health, Environmental and Occupational Health 172
Replace Dean Margeson with:
Dean Margeson United States
Jessica Kohlschmidt United States
Dong‐ming Yao China
Kelsi B. Holland United States
Bennett Adam Caughey United States
Fen‐Yu Lee Taiwan
Olivier Nibourel France
Tamara Weiss Germany
Anne Murati France
Ruth Knops Netherlands
Dean Margeson United States View profile →
Citations per field, relative to Yue-Zhong Wu
Yue-Zhong Wu · 1×
Citations per year, relative to Yue-Zhong Wu
Yue-Zhong Wu · 1×

Countries citing papers authored by Yue-Zhong Wu

Since Specialization
Citations

This map shows the geographic impact of Yue-Zhong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yue-Zhong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yue-Zhong Wu more than expected).

Fields of papers citing papers by Yue-Zhong Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yue-Zhong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yue-Zhong Wu. The network helps show where Yue-Zhong Wu may publish in the future.

Co-authorship network of co-authors of Yue-Zhong Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Yue-Zhong Wu. A scholar is included among the top collaborators of Yue-Zhong Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yue-Zhong Wu. Yue-Zhong Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
# Work Indexed citations
1
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
2024 ·Blood ·(unknown), Brian Giacopelli, Kari G. Rabe, (unknown), Yue-Zhong Wu, Huihuang Yan, Tait D. Shanafelt, Sameer A. Parikh, Wei Ding, Paul J. Hampel, (unknown), James R. Cerhan, Celine M. Vachon, Neil E. Kay, Curtis A. Hanson, Alexander S. Parker, Esteban Braggio, Susan L. Slager, Christopher C. Oakes
2
2
Abstract LB-102: Extranodal natural killer/T cell lymphoma (ENKTL) exhibits an unprecedented degree of global DNA hypermethylation, providing a potent targeted therapy in vivo
2019 ·Cancer Research ·Christoph Weigel, Bethany L. Mundy-Bosse, Yue-Zhong Wu, Kathleen McConnell, Anjali Mishra, Michael A. Caligiuri, Robert A. Baiocchi, Yasodha Natkunam, Pierluigi Porcu, Jonathan E. Brammer, Aharon G. Freud, Christopher C. Oakes
1
3
Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia
2016 ·Blood ·Brian Giacopelli, Amy S. Ruppert, Yue-Zhong Wu, Laura Z. Rassenti, William G. Wierda, R. Kanti, Neil E. Kay, Jennifer R. Brown, Thomas J. Kipps, John C. Byrd, Christopher C. Oakes
4
4
Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients
2013 ·Journal of Clinical Oncology ·Guido Marcucci, Kati Maharry, Klaus H. Metzeler, Stefano Volinia, Yue-Zhong Wu, Krzysztof Mrózek, Deedra Nicolet, Jessica Kohlschmidt, Susan P. Whitman, Jason H. Mendler, Sebastian Schwind, Heiko Becker, Ann‐Kathrin Eisfeld, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Ramiro Garzon, Michael A. Caligiuri, Richard M. Stone, Clara D. Bloomfield
137
5
The Clinical Role of Micrornas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts)
2012 ·Blood ·Guido Marcucci, Kati Maharry, Klaus H. Metzeler, Stefano Volinia, Yue-Zhong Wu, Krzysztof Mrózek, Deedra Nicolet, (unknown), Susan P. Whitman, Jason H. Mendler, Sebastian Schwind, Heiko Becker, Ann‐Kathrin Eisfeld, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Ramiro Garzon, Michael A. Caligiuri, Richard M. Stone, Clara D. Bloomfield
1
6
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia
2011 ·Blood ·Sebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, Michael D. Radmacher, Krzysztof Mrózek, Kati Maharry, Heiko Becker, Klaus H. Metzeler, Susan P. Whitman, Yue-Zhong Wu, Bayard L. Powell, Maria R. Baer, Jonathan E. Kolitz, Andrew J. Carroll, Richard A. Larson, Michael A. Caligiuri, Clara D. Bloomfield
37
7
Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML)
2011 ·Blood ·Alison R. Walker, Klaus H. Metzeler, Susan M. Geyer, Heiko Becker, Sebastian Schwind, Susan P. Whitman, John Curfman, Yue-Zhong Wu, Danilo Perrotti, Rebecca B. Klisovic, Ramiro Garzon, William Blum, Guido Marcucci
2
8
Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and Microrna (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study
2010 ·Blood ·Heiko Becker, Kati Maharry, Michael D. Radmacher, Dean Margeson, Krzysztof Mrózek, Susan P. Whitman, Yue-Zhong Wu, Klaus H. Metzeler, Sebastian Schwind, Kelsi B. Holland, Jonathan E. Kolitz, Andrew J. Carroll, Michael A. Caligiuri, Maria R. Baer, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield
1
9
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
2010 ·Blood ·Sebastian Schwind, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Kelsi B. Holland, Dean Margeson, Heiko Becker, Susan P. Whitman, Yue-Zhong Wu, Klaus H. Metzeler, Bayard L. Powell, Jonathan E. Kolitz, Thomas H. Carter, Joseph O. Moore, Maria R. Baer, Andrew J. Carroll, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield
77
10
The Mll PTD and Flt3 ITD Double Knock-In Mouse Develops Acute Leukemia and Recapitulates Phenotypic, Molecular and Epigenetic Characteristics of the Counterpart Human Acute Myeloid Leukemia
2010 ·Blood ·Nicholas A. Zorko, Susan P. Whitman, Kelsie M. Bernot, (unknown), Ronald F. Siebenaler, Shujun Liu, Yue-Zhong Wu, (unknown), Xiaoli Zhang, David Jarjoura, Zhiliang Xie, Kenneth K. Chan, Adrienne M. Dorrance, Benjamin H. Lee, Roger Briesewitz, Danilo Perrotti, Guido Marcucci, Michael A. Caligiuri
3
11
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study breakdown →
2010 ·Journal of Clinical Oncology ·Guido Marcucci, Kati Maharry, Yue-Zhong Wu, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Kelsi B. Holland, Susan P. Whitman, Heiko Becker, Sebastian Schwind, Klaus H. Metzeler, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield
548
12
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
2009 ·Journal of Clinical Oncology ·Heiko Becker, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Susan P. Whitman, Yue-Zhong Wu, Sebastian Schwind, Peter Paschka, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield
241
13
Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.
2009 ·Blood ·Heiko Becker, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Susan P. Whitman, Peter Paschka, Dean Margeson, Yue-Zhong Wu, Sebastian Schwind, Christian Langer, Maria R. Baer, Andrew J. Carroll, Michael A. Caligiuri, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield
19
14
Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.
2009 ·Blood ·Shujun Liu, Lai‐Chu Wu, Jiuxia Pang, Ramasamy Santhanam, Sebastian Schwind, Yue-Zhong Wu, Christopher Hickey, Jianhua Yu, Anjali Mishra, Heiko Becker, Chenglong Li, Roger Briesewitz, Robert A. Baiocchi, Kenneth K. Chan, Michael A. Caligiuri, John C. Byrd, Danilo Perrotti, Ramiro Garzon, Guido Marcucci
2
15
MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells.
2009 ·Blood ·Christopher Hickey, Sebastian Schwind, Heiko Becker, Houda Alachkar, Ramiro Garzon, Yue-Zhong Wu, Shujun Liu, Danilo Perrotti, Guido Marcucci
5
16
CpG Island Methylation in a Mouse Model of Lymphoma Is Driven by the Genetic Configuration of Tumor Cells
2007 ·PLoS Genetics ·René Opavský, Shu‐Huei Wang, Prashant Trikha, Aparna Raval, Yuan Huang, Yue-Zhong Wu, Blanca Rodríguez, Benjamin J. Keller, Sandya Liyanarachchi, Wei Guo, Ramana V. Davuluri, Michael Weinstein, Dean W. Felsher, Michael C. Ostrowski, (unknown), Christoph Plass
34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dean Margeson Breakdown of academic impact, for papers by Jessica Kohlschmidt Breakdown of academic impact, for papers by Dong‐ming Yao Breakdown of academic impact, for papers by Kelsi B. Holland Breakdown of academic impact, for papers by Bennett Adam Caughey Breakdown of academic impact, for papers by Fen‐Yu Lee Breakdown of academic impact, for papers by Olivier Nibourel Breakdown of academic impact, for papers by Tamara Weiss Breakdown of academic impact, for papers by Anne Murati Breakdown of academic impact, for papers by Ruth Knops
Rankless by CCL
2026